Compare CSX Corporation (CSX) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs CVS Health Corp — how do they compare? CSX Corporation trades at $47.6 (market cap $87.70B), while CVS Health Corp trades at $85.46 (market cap $112.29B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and CVS Health Corp for 83 Days on average.
| CSX | CVS | |
|---|---|---|
Market Cap | $87.70B | $112.29B |
Volume | 6,980,781 | 7,763,676 |
Sector | Industrials | Health |
52-Week High | $53.21 | $110.60 |
52-Week Low | $33.68 | $70.08 |
Typical Hold Time | 55 Days | 83 Days |
Enterprise Value | $105.66B | $174.64B |
Dividend Yield | 1.18% | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% today, with a bearish technical signal from moving averages. The company reported mixed quarterly EPS results, missing in Q4 2025 but beating in Q1 and Q2 2026. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though 2026 projections show a rebound to $14.5B. Analyst consensus is bullish with a $51 price target, supported by strong institutional buying activity reported in recent SEC filings.
The outlook for CSX hinges on earnings recovery and operational efficiency gains. Key opportunities include pricing power in freight rail and dividend growth, while risks involve revenue volatility and high debt levels. The stock offers potential upside to the consensus target but faces headwinds from economic cycles affecting freight demand.
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
